Spiriva is expensive primarily because of patent protections that have blocked generic competition for decades, a uniquely complex inhaler device that costs more to manufacture than standard inhalers, and the U.S. drug pricing system that allows manufacturers to set prices far above what other countries pay. A 30-day supply of Spiriva HandiHaler costs about $344 in the United States, compared to $106 in Canada and as low as $60 through international pharmacies.
Patent Protection Has Blocked Competition
The biggest driver of Spiriva’s high price is the same force behind most expensive brand-name drugs: patents. Boehringer Ingelheim, the manufacturer, holds multiple patents on Spiriva that prevent other companies from making cheaper versions. While the FDA approved the first generic version of the Spiriva HandiHaler (the dry-powder capsule form) in 2023, made by Lupin, the newer Spiriva Respimat still has no generic equivalent.
The Respimat version is protected by a web of patents that don’t begin expiring until October 2026, with additional patents extending as far out as April 2031. Some of these extensions come from pediatric exclusivity, which grants extra months of protection when a manufacturer studies a drug in children. Each patent covers a different aspect of the product, whether the drug formulation, the delivery mechanism, or the device engineering, making it difficult for generic manufacturers to bring a competing product to market even as individual patents expire.
The Respimat Device Is Engineered Like Microchip Hardware
Spiriva Respimat isn’t a simple pressurized canister like many inhalers. It uses a “soft mist” technology that required Boehringer Ingelheim to essentially invent new manufacturing processes from scratch. The core of the device is a component called the uniblock, made from silicon sandwiched between glass plates, with channels etched to sub-micrometer precision using the same photolithographic techniques used in semiconductor manufacturing. The accuracy of this process is better than 0.1 micrometers, roughly 1,000 times thinner than a human hair.
The silicon and glass layers are bonded together under high temperature and a strong electrical field to create leak-proof microfluidic channels without any adhesive. The drug solution sits in a collapsible double-walled bag inside an aluminum cylinder, and the device’s polymer components must withstand enormous mechanical stress from an internal spring over the product’s entire lifespan. Because nothing like this existed before, the company had to design and build custom assembly lines with automated vision systems checking quality at nearly every stage of production. All of this adds real cost per unit that a standard dry-powder inhaler simply doesn’t carry.
U.S. Prices Are Three to Six Times Higher Than Abroad
As of mid-2025, a single pack of 30 Spiriva HandiHaler capsules costs about $344 in the United States, $106 in Canada, and as little as $60 from verified international online pharmacies. That gap isn’t about manufacturing or shipping costs. It exists because the U.S. is one of the few countries where drug manufacturers can set their own prices without government negotiation or price caps.
Countries like Canada use regulatory boards to assess whether a drug’s price is reasonable relative to its clinical benefit and then negotiate accordingly. The U.S. has historically lacked this kind of leverage for most medications, though recent legislation has begun to change that for select drugs covered under Medicare. Spiriva’s price in the U.S. reflects what the market will bear, not what the drug costs to produce or what patients in other countries pay for the identical product.
How Spiriva Compares to Other Inhalers in Its Class
Spiriva belongs to a class of long-acting bronchodilators that relax the muscles around your airways. It’s not the only option. Comparing daily costs across the class shows that Spiriva falls in line with some competitors but costs more than others. Glycopyrronium (sold as Seebri in some markets) runs roughly $1.77 per day, while Spiriva costs about $2.17 per day and aclidinium (Tudorza) comes in at around $2.35 per day. On an annual basis, that puts Spiriva at approximately $791 compared to $646 for glycopyrronium, based on Canadian wholesale pricing. In the U.S., the spread can be wider depending on your insurance formulary and which tier each drug occupies.
The $35 Cap and Other Ways to Pay Less
In 2024, following a congressional investigation into inhaler pricing, Boehringer Ingelheim announced it would cap out-of-pocket costs for its inhaler products at $35 per month. This applies to commercially insured patients and took effect in mid-2024. If you have private insurance, this cap can dramatically reduce what you pay at the pharmacy counter, though the list price of the drug itself hasn’t changed.
For uninsured patients or those who still can’t afford the copay, Boehringer Ingelheim runs a patient assistance program through the Boehringer Cares Foundation, an independent nonprofit. Eligible patients can receive their medication at no cost. Applications can be submitted online by a healthcare provider or downloaded and mailed in English or Spanish. The program is designed for patients who lack insurance coverage or who fall below certain income thresholds.
The arrival of generic tiotropium for the HandiHaler version should also push prices down over time, though generic inhaler uptake tends to be slower than for pills because pharmacists can’t always substitute one inhaler device for another without a new prescription. If you’re currently using Spiriva Respimat and cost is a barrier, asking your prescriber whether the generic HandiHaler version or a different medication in the same class would work for you is a practical starting point.